Since its establishment in May 2000, microbio has been adhering to the concept of active innovation, focusing on the research and development of high-end products for new medicines and medical care, and gradually forming a biotechnology enterprise group with “innovation” as its core. In-depth development in new drug research and development, organic agriculture and biotechnology venture capital. While achieving corporate development and enhancing shareholders’ rights, we also fulfill our corporate social responsibility and care for our lives.
In terms of new drug research and development, Chemo young and Herbiron have obtained the new drug certificates approved by the Ministry of Health and Welfare, and have successfully developed a variety of microbial pharmaceutical technology platforms, and have repeatedly made major breakthroughs in the field of biotechnology. The Microbio has received many awards and professional awards such as Biomedical Quality Award and Biomedical Innovation Award. At the same time, Microbio continues to uphold professional and rigorous R&D management, combined with the first-class R&D team, to develop high-quality medical and health care products, including Tien Chun Boo, top quality enzyme drinks and Lee Herb series products and other patented leading products.
2000 | Established Microbio Co., Ltd. |
2001 | Longtan Plant was established and passed the GMP certification |
2004 | Microbio Co., Ltd. was established |
2004 | Established Taiwan’s first “New Drug Research and Development Center |
2006 | Microbio’s stock has been officially listed on over the counter market (4128) |
2011 | MS-20 (Chemo young) obtained the first certificate of oral solution for cancer new drug. |
2013 | Herbiron obtained the first compound herbs new drug certificate |
2016 | Joint development of the Pingtung County Nanjhou Township with ONENESS to establish PIC/S GMP Pharmaceutical Factory and Sightseeing Pharmaceutical Factory Park |
2020 | MSCI added Microbio Co., to Global Small Cap Indexes |
2021 | Announce the subsidiay Microbio (Shanghai) receives “Prior Authorisation for Import of Traditional Medicines” from Macau on Fespixon cream (ON101) |
2023 | Annouced on behalf of Microbio (Shanghai) that FESPIXON, the new drug in treating DFUs has been approved as Class 1.1 natural new drug by China NMPA |
2024 | Microbio (Shanghai) and Oneness have entered into an exclusive agreement of Fespixon commercialization with China Resources Double Crane Pharmaceutical Co., Ltd. |
2024 | Symbiota exclusively developed by Microbio Co., Ltd. achieves an Independent/Self-affirmed GRAS conclusion according to the U.S. FDA regulations. |